Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case report

Contact us

• Submission enquiries: bmccancer@biomedcentral.com
• General enquiries: ORSupport@springernature.com